Nightingale Health announced that it will open a laboratory in the United States. Additionally, Nightingale Health and the Englander Institute for Precision Medicine at Weill Cornell Medicine have signed a Letter of Intent in which the parties agree to collaborate on the adoption of Nightingale Health's proprietary technology in healthcare and medical research in the United States. The Englander Institute for Precision Medicine is a translational research hub at Weill Cornell Medicine committed to translating research findings into clinical practice, including at its branch campus in Doha, Qatar.

The institute has already significantly impacted the field of precision medicine by developing new treatments for a variety of diseases, including cancer, rare diseases, and cardiovascular disease. As part of the collaboration between the Englander Institute for Precision medicine and Nightingale Health, in addition to medical research, the parties aim to integrate Nightingale Health's proprietary blood analysis technology and disease risk assessment capabilities to Weill Cornell Medicine's clinical and research services. The healthcare applications can be based on Nightingale Health's existing capabilities such as multi-disease risk prediction models and individual diagnostic biomarkers that can replace clinical chemistry measures.

The new partnerships combined with a new laboratory will make Nightingale Health well equipped to make its proprietary blood analysis technology available locally in the largest healthcare market in the world and expand its partnerships within the medical research community. The location and opening schedule of the new laboratory will be announced at a later date.